{"schema_version":"secwatch.filing_event.v1","accession":"0000075252-23-000022","form_type":"8-K","ticker":"ACH","cik":"0000075252","company_name":"ACCENDRA HEALTH INC/VA/","filed_at":"2023-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.163503+00:00","generated_at":"2026-06-15T18:39:58.121497+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Owens & Minor posts Q1 net loss $(0.32)/share; raises 2023 guidance on Patient Direct strength","bullets":["Revenue $2.5B (+4.8% YoY); GAAP net loss $24.4M vs. net income $39.3M in Q1 2022.","Adjusted EPS $0.05 vs. $0.96 prior year; adjusted operating income $47.7M vs. $104.9M.","Patient Direct segment drove margin expansion; Products & Healthcare Services saw destocking pressure.","Raised 2023 guidance: revenue $10.35-10.55B, adjusted EBITDA $480-510M (from $465-490M).","Generated $158M operating cash flow; paid down $117M debt in Q1."],"urls":{"canonical":"https://secwatch.observer/filing/0000075252-23-000022","json":"https://secwatch.observer/filing/0000075252-23-000022.json","markdown":"https://secwatch.observer/filing/0000075252-23-000022.md","text":"https://secwatch.observer/filing/0000075252-23-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/75252/000007525223000022/0000075252-23-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/75252/000007525223000022/omi-20230505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T18:39:58.121497+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"744316dfe03812d77c125fa106a4b3d258feb6bd","claim":"ACCENDRA HEALTH INC/VA/ reported the first quarter ended March 31, 2023 results: revenue $2,523, net income $(24.4), EPS $(0.32). Guidance raised.","evidence_excerpt":"Financial Summary (1) ($ in millions, except per share data) 1Q23 1Q22 Revenue $2,523 $2,407 Operating income, GAAP $9.8 $61.1 Adj. Operating Income, Non-GAAP $47.7 $104.9 Net (loss) income, GAAP $(24.4) $39.3 Adj. Net Income, Non-GAAP $3.6 $72.8 Adj. EBITDA, Non-GAAP $108.7 $122.6 Net (loss) income per common share, GAAP $(0.32) $0.52 Adj. Net Income per share, Non-GAAP $0.05 $0.96","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/75252/000007525223000022/0000075252-23-000022-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$2,523"},{"label":"Net income","value":"$(24.4)"},{"label":"EPS","value":"$(0.32)"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}